BG100192A - 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents - Google Patents
2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agentsInfo
- Publication number
- BG100192A BG100192A BG100192A BG10019295A BG100192A BG 100192 A BG100192 A BG 100192A BG 100192 A BG100192 A BG 100192A BG 10019295 A BG10019295 A BG 10019295A BG 100192 A BG100192 A BG 100192A
- Authority
- BG
- Bulgaria
- Prior art keywords
- complexes
- pyridylmethylenepolyazamacrocyclophosphonic
- derivatives
- contrast agents
- acids
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 239000002872 contrast media Substances 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/281—Means for the use of in vitro contrast agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/057,588 US5462725A (en) | 1993-05-06 | 1993-05-06 | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| PCT/US1994/005009 WO1994026275A1 (fr) | 1993-05-06 | 1994-05-05 | Acides 2-pyridylmethylenepolyazamacrocyclophosphoniques, complexes et derives de ces acides, utilisables comme agents de contraste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG100192A true BG100192A (en) | 1996-12-31 |
Family
ID=22011534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG100192A BG100192A (en) | 1993-05-06 | 1995-12-05 | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5462725A (fr) |
| EP (1) | EP0711300B1 (fr) |
| JP (1) | JPH08510245A (fr) |
| CN (1) | CN1125905A (fr) |
| AT (1) | ATE227297T1 (fr) |
| AU (1) | AU678583B2 (fr) |
| BG (1) | BG100192A (fr) |
| CA (1) | CA2162174A1 (fr) |
| CZ (1) | CZ289595A3 (fr) |
| DE (1) | DE69431660T2 (fr) |
| FI (1) | FI955319A (fr) |
| HU (1) | HUT74565A (fr) |
| LV (1) | LV11430B (fr) |
| NO (1) | NO301829B1 (fr) |
| PL (1) | PL311643A1 (fr) |
| SG (1) | SG46458A1 (fr) |
| WO (1) | WO1994026275A1 (fr) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409689A (en) * | 1993-08-13 | 1995-04-25 | Concat, Ltd. | MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms |
| DE19523891C1 (de) * | 1995-06-30 | 1996-11-21 | Hoechst Ag | Chirale Mangan-triazanonankomplexe und Verfahren zu ihrer Herstellung |
| CA2251924C (fr) * | 1996-04-19 | 2006-05-30 | The Dow Chemical Company | Chelates fluorescents utilises en tant qu'agents visuels destines a l'imagerie et specifiques de certains tissus |
| US6685914B1 (en) | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
| EP1362861B1 (fr) * | 1999-09-13 | 2005-12-14 | Bristol-Myers Squibb Pharma Company | Chelatants macrocycliques destinés à des produits métallopharmaceutiques |
| CA2382057A1 (fr) * | 1999-09-13 | 2001-03-22 | Bristol-Myers Squibb Pharma Company | Chelateurs macrocycliques destines a des produits metallopharmaceutiques |
| US7338651B2 (en) * | 2001-09-04 | 2008-03-04 | Texas Tech University System | Multi-use multimodal imaging chelates |
| ATE309254T1 (de) | 2001-10-22 | 2005-11-15 | Univ Texas Tech | Gewebespezifische fluoreszierende chelate |
| US9031634B2 (en) * | 2002-05-17 | 2015-05-12 | Christopher Flask | Chemical shift markers for improved wireless fiducial marker tracking |
| EP1778699A4 (fr) * | 2004-08-10 | 2009-02-25 | Dow Global Technologies Inc | Chelateurs et composes chelates de ciblage |
| EP1637524A1 (fr) * | 2004-09-20 | 2006-03-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dérivés de 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane 10-substitués utilisables comme agents de contraste |
| CA2580141C (fr) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Anticorps et conjugues produits avec de la cysteine |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1805188A4 (fr) * | 2004-09-30 | 2010-03-03 | Mds Analytical Technologies Us | Complexes de lanthanides luminescents |
| WO2007140371A2 (fr) | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Anticorps et immuno-conjugués, et leurs utilisations |
| RU2639543C9 (ru) | 2006-10-27 | 2018-06-14 | Дженентек, Инк. | Антитела и иммуноконъюгаты и их применения |
| AR065271A1 (es) | 2007-02-09 | 2009-05-27 | Genentech Inc | Anticuerpos anti-robo4 y sus usos |
| AU2008276128B2 (en) | 2007-07-16 | 2013-10-10 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
| ES2579323T3 (es) | 2007-07-16 | 2016-08-09 | Genentech, Inc. | Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso |
| CL2009000062A1 (es) | 2008-01-31 | 2010-05-14 | Genentech Inc | Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas. |
| US8499251B2 (en) | 2009-01-07 | 2013-07-30 | Microsoft Corporation | Virtual page turn |
| PE20120878A1 (es) | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS |
| PL2896404T3 (pl) | 2009-06-04 | 2017-12-29 | Novartis Ag | Sposoby identyfikacji miejsc koniugacji IgG |
| RU2580038C2 (ru) | 2009-12-04 | 2016-04-10 | Дженентек, Инк. | Мультиспецифические антитела, аналоги антител, композиции и способы |
| EP2577310B1 (fr) | 2010-06-03 | 2018-11-14 | F.Hoffmann-La Roche Ag | Imagerie par immuno-tep d'anticorps et d'immunoconjugués et utilisations correspondantes |
| RU2626537C2 (ru) | 2010-06-08 | 2017-07-28 | Дженентек, Инк. | Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты |
| MX353951B (es) | 2012-07-04 | 2018-02-07 | Hoffmann La Roche | Anticuerpos de anti-teofilina y metodos de uso. |
| WO2014006124A1 (fr) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Conjugués anticorps-antigène liés par covalence |
| EP3339328A1 (fr) | 2012-07-04 | 2018-06-27 | F. Hoffmann-La Roche AG | Anticorps anti-biotine et procédés d'utilisation |
| CA2933384A1 (fr) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Anticorps bispecifiques diriges contre les haptenes/les recepteurs de la barriere hemato-encephalique, complexes en integrant et leur utilisation en tant que navettes a travers la barriere hemato-encephalique |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| CA2930154A1 (fr) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Conjugues helicar-anticorps anti-helicar lies de facon covalente et utilisations associees |
| KR20170052600A (ko) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | 시스테인 가공된 항체 및 콘주게이트 |
| JP6618539B2 (ja) | 2014-12-17 | 2019-12-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ソルターゼを使用した酵素媒介性のポリペプチドコンジュゲーションのための方法 |
| JP6895953B2 (ja) | 2015-09-25 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ソルターゼａを利用してチオエステルを作製するための方法 |
| WO2017050866A1 (fr) | 2015-09-25 | 2017-03-30 | F. Hoffmann-La Roche Ag | Nouvelle sortase a soluble |
| EP3353201B1 (fr) | 2015-09-25 | 2021-09-08 | F. Hoffmann-La Roche AG | Chaînes lourdes de l'immunoglobuline recombinante comprenant une boucle de conjugaison par la sortase et leurs conjugués |
| EP3353314A1 (fr) | 2015-09-25 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Transamidation utilisant de la sortase a dans des solvants eutectiques profonds |
| WO2017167712A1 (fr) | 2016-03-30 | 2017-10-05 | F. Hoffmann-La Roche Ag | Sortase améliorée |
| KR102495650B1 (ko) | 2017-04-12 | 2023-02-02 | 에프. 호프만-라 로슈 아게 | 알데히드 함유 표적 분자의 라벨링 방법 |
| EP3652214A1 (fr) | 2017-07-13 | 2020-05-20 | H. Hoffnabb-La Roche Ag | Nouvel agent de liaison et dosage pour pivka |
| JP7403444B2 (ja) | 2017-10-20 | 2023-12-22 | エフ． ホフマン－ラ ロシュ アーゲー | 抗体の複写保護措置 |
| EP3717517A1 (fr) | 2017-11-30 | 2020-10-07 | H. Hoffnabb-La Roche Ag | Anticorps anti-pd-l1 et leurs procédés d'utilisation pour la détection de pd-l1 |
| EP3492460A1 (fr) * | 2017-12-01 | 2019-06-05 | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. | Composés pour la séparation d'éléments de terres rares, procédé de séparation et utilisation associée |
| CN111971300A (zh) | 2018-03-14 | 2020-11-20 | 豪夫迈·罗氏有限公司 | 新颖的抗-肌钙蛋白t抗体 |
| WO2019175131A1 (fr) | 2018-03-14 | 2019-09-19 | F. Hoffmann-La Roche Ag | Procédé de maturation d'affinité d'anticorps |
| EP3781600A1 (fr) | 2018-04-18 | 2021-02-24 | F. Hoffmann-La Roche AG | Nouveaux anticorps anti-thymidine kinase |
| EP3844503B1 (fr) | 2018-08-31 | 2024-05-29 | F. Hoffmann-La Roche AG | Thymidine kinase (tk-1) dans la détermination d'indices de pronostic pour le dlbcl |
| US20220001043A1 (en) | 2018-09-28 | 2022-01-06 | Imaginab, Inc. | Cd8 imaging constructs and methods of use thereof |
| WO2021013786A1 (fr) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | S100a6 en tant que biomarqueur du sang pour le diagnostic non invasif de l'endométriose |
| KR20220024782A (ko) | 2019-07-22 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | 자궁내막증의 비침습적 진단을 위한 혈액 바이오마커로서의 s100a8 |
| BR112022001140A2 (pt) | 2019-07-22 | 2022-03-15 | Hoffmann La Roche | Métodos para avaliar se um paciente tem endometriose ou está em risco de desenvolver endometriose, selecionar um paciente para terapia e monitorar um paciente que sofre de endometriose ou que está sendo tratado para endometriose |
| BR112022000172A2 (pt) | 2019-07-22 | 2022-02-22 | Hoffmann La Roche | Métodos para avaliar se uma paciente tem endometriose, para selecionar uma paciente para terapia e para monitorar uma paciente |
| WO2021013781A1 (fr) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | Substance p en tant que biomarqueur du sang pour le diagnostic non invasif de l'endométriose |
| JP2023502360A (ja) | 2019-11-15 | 2023-01-24 | エフ．ホフマン－ラ ロシュ アーゲー | 患者試料における質量分析測定のためのβ－ラクタム抗生物質の誘導体化 |
| KR20230092930A (ko) | 2020-10-30 | 2023-06-26 | 에프. 호프만-라 로슈 아게 | 담관암종의 표지자로서의 timp1 |
| US20230406909A1 (en) | 2020-11-02 | 2023-12-21 | Roche Diagnostics Operations, Inc. | Sars-cov-2 nucleocapsid antibodies |
| WO2022207628A1 (fr) | 2021-03-30 | 2022-10-06 | F. Hoffmann-La Roche Ag | Scf comme biomarqueur sanguin pour le diagnostic non invasif de l'endométriose |
| EP4314838A1 (fr) | 2021-04-01 | 2024-02-07 | F. Hoffmann-La Roche AG | Psp94 utilisée en tant que biomarqueur sanguin pour le diagnostic non invasif de l'endométriose |
| EP4341700A1 (fr) | 2021-05-17 | 2024-03-27 | F. Hoffmann-La Roche AG | Sfrp4 en tant que biomarqueur sanguin pour le diagnostic non invasif de l'adénomyose |
| CN118434762A (zh) | 2021-10-26 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 对SARS-CoV-2 RBD具有特异性的单克隆抗体 |
| CN118382636A (zh) | 2021-12-17 | 2024-07-23 | 豪夫迈·罗氏有限公司 | 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体 |
| WO2023131594A1 (fr) | 2022-01-05 | 2023-07-13 | F. Hoffmann-La Roche Ag | Dérivatisation de composés dans des échantillons de patients pour la pharmacovigilance thérapeutique (tdm) |
| WO2023247752A1 (fr) | 2022-06-23 | 2023-12-28 | F. Hoffmann-La Roche Ag | Procédé de diagnostic de l'endométriose et de classification du stade de l'endométriose |
| WO2024017983A1 (fr) | 2022-07-22 | 2024-01-25 | F. Hoffmann-La Roche Ag | Protéine de type météorine (metrnl) utilisée en tant que biomarqueur (sang) pour le diagnostic du syndrome des ovaires polykystiques |
| WO2024017982A1 (fr) | 2022-07-22 | 2024-01-25 | F. Hoffmann-La Roche Ag | Leukotriène a4 hydrolase (lta4h) en tant que biomarqueur (sang) pour le diagnostic du syndrome des ovaires polykystiques |
| WO2024017985A1 (fr) | 2022-07-22 | 2024-01-25 | F. Hoffmann-La Roche Ag | Protéine 1 de liaison au facteur de croissance des fibroblastes (fgfbp1) utilisée en tant que biomarqueur (sanguin) pour le diagnostic du syndrome des ovaires polykystiques |
| WO2024030772A1 (fr) * | 2022-08-01 | 2024-02-08 | Portland State University | Agents de contraste à haute relaxivité et préparation stéréosélective |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2609390A (en) * | 1950-06-01 | 1952-09-02 | Frederick C Bersworth | Phosphonic alkylene polyamino acids and method of producing same |
| US3336221A (en) * | 1964-11-05 | 1967-08-15 | Calgon Corp | Method of inhibiting precipitation and scale formation |
| US3331773A (en) * | 1966-07-22 | 1967-07-18 | Grace W R & Co | Process for inhibiting precipitation in water |
| US3434969A (en) * | 1967-08-11 | 1969-03-25 | Calgon Corp | Scale inhibiting |
| US4980148A (en) * | 1985-02-06 | 1990-12-25 | Mallinckrodt, Inc. | Methods for enhancing magnetic resonance imaging |
| US4880008A (en) * | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
| US4899755A (en) * | 1985-05-08 | 1990-02-13 | The General Hospital Corporation | Hepatobiliary NMR contrast agents |
| JP2831073B2 (ja) * | 1988-06-24 | 1998-12-02 | ザ ダウ ケミカル カンパニー | 大環状二官能キレート剤、その錯体及びそれらの抗体接合体 |
| GB8914543D0 (en) * | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
| US5247077A (en) * | 1989-06-23 | 1993-09-21 | Celltech Limited | Tri-aza macrocycles and processes for their preparation |
| FR2672051B1 (fr) * | 1991-01-24 | 1993-05-21 | Guerbet Sa | Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique. |
| IL106159A0 (en) * | 1992-06-30 | 1993-10-20 | Dow Chemical Co | Targeted delivery of growth factors for bone regeneration |
| EP0588229A3 (en) * | 1992-09-12 | 1994-06-15 | Hoechst Ag | Macrocyclic chelating agents for the preparation of technetium or rhenium complexes |
-
1993
- 1993-05-06 US US08/057,588 patent/US5462725A/en not_active Expired - Fee Related
-
1994
- 1994-05-05 WO PCT/US1994/005009 patent/WO1994026275A1/fr active IP Right Grant
- 1994-05-05 CN CN94192527.7A patent/CN1125905A/zh active Pending
- 1994-05-05 HU HU9503174A patent/HUT74565A/hu unknown
- 1994-05-05 PL PL94311643A patent/PL311643A1/xx unknown
- 1994-05-05 JP JP6525558A patent/JPH08510245A/ja not_active Ceased
- 1994-05-05 AU AU69447/94A patent/AU678583B2/en not_active Ceased
- 1994-05-05 CZ CZ952895A patent/CZ289595A3/cs unknown
- 1994-05-05 CA CA002162174A patent/CA2162174A1/fr not_active Abandoned
- 1994-05-05 DE DE69431660T patent/DE69431660T2/de not_active Expired - Fee Related
- 1994-05-05 SG SG1996004873A patent/SG46458A1/en unknown
- 1994-05-05 AT AT94917922T patent/ATE227297T1/de not_active IP Right Cessation
- 1994-05-05 EP EP94917922A patent/EP0711300B1/fr not_active Expired - Lifetime
-
1995
- 1995-11-06 FI FI955319A patent/FI955319A/fi unknown
- 1995-11-06 NO NO954440A patent/NO301829B1/no unknown
- 1995-12-05 BG BG100192A patent/BG100192A/xx unknown
- 1995-12-06 LV LVP-95-362A patent/LV11430B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT74565A (en) | 1997-01-28 |
| JPH08510245A (ja) | 1996-10-29 |
| NO301829B1 (no) | 1997-12-15 |
| FI955319A (fi) | 1995-12-22 |
| AU6944794A (en) | 1994-12-12 |
| LV11430A (lv) | 1996-08-20 |
| SG46458A1 (en) | 1998-02-20 |
| EP0711300A1 (fr) | 1996-05-15 |
| CZ289595A3 (en) | 1997-01-15 |
| WO1994026275A1 (fr) | 1994-11-24 |
| CN1125905A (zh) | 1996-07-03 |
| EP0711300A4 (fr) | 1996-03-12 |
| NO954440D0 (no) | 1995-11-06 |
| HU9503174D0 (en) | 1996-01-29 |
| EP0711300B1 (fr) | 2002-11-06 |
| DE69431660T2 (de) | 2003-08-21 |
| CA2162174A1 (fr) | 1994-11-24 |
| US5462725A (en) | 1995-10-31 |
| PL311643A1 (en) | 1996-03-04 |
| DE69431660D1 (de) | 2002-12-12 |
| FI955319A0 (fi) | 1995-11-06 |
| AU678583B2 (en) | 1997-06-05 |
| LV11430B (en) | 1997-04-20 |
| NO954440L (no) | 1996-01-05 |
| ATE227297T1 (de) | 2002-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9503174D0 (en) | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents | |
| HU9502023D0 (en) | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof for use as contrast agents | |
| AU2054097A (en) | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents | |
| CA2123048A1 (fr) | Derives tetrazole d'acides biliaires, procedes pour leur preparation et leur utilisation comme medicaments | |
| AU4299496A (en) | Novel multiple-substituent dtpa derivatives and metal complexes thereof, pharmaceutical compositions containing such complexes, their use in diagnosis and therapy, methods ofpreparing the complexing agents and complexes and methods of preparing the pharmaceutical compositions | |
| CA2001765A1 (fr) | Chelants possedant une fonctionnalite d'ortho-ligature et ses complexes | |
| IL104060A0 (en) | Bicyclopolyazamacrocyclophosphonic acids,their complexes and conjugates,for use as contrast agents,and processes for their preparation | |
| WO1999011256A8 (fr) | L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme | |
| ZA949604B (en) | Haloaryl-substituted metal complexes pharmaceutical agents containing these complexes, their use in diagnosis, as well as process for the production of the complexes and agents | |
| NO954442L (no) | Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling | |
| MY141501A (en) | Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents and processes for their preparation | |
| MY109649A (en) | Bicyclopol yazamacrocyclocarboxylic acid complexes, and conjugates, processes for their prepration, and use as contrast agents |